Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosurveillance

Risk Stratification of Patients with Suspected Ebola

by Global Biodefense Staff
April 13, 2015

Abdominal pain, fever and unexplained bleeding – which are commonly believed to indicate infection with the Ebola virus — are not significantly predictive of the disease, according to the results of a study examining a new Ebola Prediction Score published online in Annals of Emergency Medicine.

“Not surprisingly, contact with a suspected or confirmed Ebola patient was the strongest independent predictor of having Ebola,” said lead study author Adam Levine, MD, MPH, of Rhode Island Hospital in Providence, R.I. “What was surprising was that abdominal pain in combination with other Ebola-like symptoms actually turned out to be negatively predictive of Ebola. This may be because those patients actually had another disease like typhoid, which is more likely to cause abdominal pain.”

Current World Health Organization and Medecins san Frontieres symptoms lists for Ebola include fever, nausea with vomiting, diarrhea, fatigue, abdominal pain, loss of appetite, muscle pain, joint pain, headache, difficulty breathing, difficulty swallowing, hiccups, unexplained bleeding and exposure to a suspected or confirmed Ebola patient within 21 days.

Dr. Levin’s Ebola Prediction Score tool demonstrates that just six of those symptoms together — contact with an infected person, diarrhea, loss of appetite, muscle pain, difficulty swallowing and absence of abdominal pain — accurately predicted infection with Ebola.

Diagnosing Ebola remains a significant challenge because initial symptoms are similar to those of many other diseases. This is the first study to empirically derive and internally validate a clinical prediction model for laboratory-confirmed Ebola. The Ebola Prediction Score can be used by clinicians in the context of an active Ebola epidemic for the purpose of separating patients in an isolation center.

“The current Ebola outbreak in West Africa is the largest on record and has overwhelmed the capacity of both local health systems and the international community,” said Dr. Levine. “The Ebola Prediction Score will help clinicians risk-stratify patients already meeting one or more suspect definitions of Ebola. Given the devastation this epidemic has already caused, a low-cost, point-of-care test that can rapidly and definitively exclude Ebola in patients should be a research priority.”

Ebola has affected 24,000 persons during the current epidemic, which is the largest recorded outbreak of Ebola in history. Over 10,000 people have died in West Africa, mainly in Sierra Leone, Liberia and Guinea.

Read the study: Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients with Suspected Ebola Virus Disease.

Tags: EbolaEmerging Threats

Related Posts

New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Why Do Some of the Outbreak Genomes Have More Mutations Than Others?
Biosurveillance

Virginia Institutes Partner to Join National Pathogen Genomics Centers of Excellence Network

October 25, 2022
Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations
Medical Countermeasures

Study: Cash Incentives and Lotteries Do Little to Increase Adult Vaccinations

October 25, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC